Key facts
- It has raised $13.7M across 3 recorded rounds; the latest was Early Stage VC ($9.9M) in Sep 2025.
- Mati Therapeutics has filed 6 Form Ds with the SEC since 2013, most recently Oct 2025 ($9.9M sold to 13 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·Watchlist + deal alerts for Mati Therapeutics
Funding rounds
3 roundsAbout Mati Therapeutics
Developer of a novel, non-invasive sustained drug delivery platform designed to deliver medication to the surface of the eye for improved treatment of ocular conditions. The company's platform offers a platform that provides controlled, long-lasting drug release, reducing the need for frequent dosing, enabling patients with glaucoma, dry eye syndrome, ocular allergies, and post-cataract surgery care to experience enhanced treatment adherence and effectiveness.
- Sector
- Healthcare
- HQ
- Austin, TX, United States
- Founded
- 2012
- Employees
- 10
- Website
- matitherapeutics.com/
- Ownership
- Privately Held (backing)
Mati Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Mati Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Mati Therapeutics in its N-PORT filings yet. We sweep new filings monthly.